SCHEMBL29619047

SCHEMBL29619047

Cc1noc(C)c1-c1cc(NC(=O)C2CC2)ccc1OCCN1CCC(CC(=O)O)CC1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 10/20 0.43
HTR2C P28335 9/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
BRD4 O60885 1/20 0.41
BRD2 P25440 1/20 0.41
BRD3 Q15059 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PDE5A O76074 1/20 0.40
HTR1A P08908 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619104 0.93 HTR2A (0.43) HTR2AHTR2CMAPTLMNASMN1; SMN2
SCHEMBL29619056 0.90 HTR2A (0.53) HTR2AHTR2CMAPTLMNASMN1; SMN2
SCHEMBL29619051 0.90 HTR2A (0.51) HTR2AHTR2C
SCHEMBL29619101 0.90 HTR2A (0.49) HTR2AHTR2CBRD4BRD2BRD3
SCHEMBL31677866 0.89 HTR2A (0.43) HTR2AHTR2CPDE5AHTR1AHTR1D
SCHEMBL29619130 0.88 HTR2A (0.55) HTR2AHTR2CMAPTLMNASMN1; SMN2
SCHEMBL29619153 0.88 HTR2A (0.51) HTR2AHTR2CBRD4BRD2BRD3
SCHEMBL29619084 0.87 HTR2A (0.48) HTR2AHTR2CMAPTLMNASMN1; SMN2
SCHEMBL29619116 0.87 HTR2A (0.48) HTR2AHTR2CMAPTLMNASMN1; SMN2
SCHEMBL29619059 0.87 HTR2A (0.52) HTR2AHTR2CMAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2024-11-14 US disclosed
EP-4236942-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2023-09-06 EP disclosed
WO-2022093850-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376090-A1 ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO HTR2A, HTR5A, HTR1A HTR2A 1/4885HTR2C 4/4885MAPT 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.